Eli Lilly and Company (LLY)vsScienture Holdings, Inc. (SCNX)
LLY
Eli Lilly and Company
$1,115.70
-0.65%
HEALTHCARE · Cap: $994.92B
SCNX
Scienture Holdings, Inc.
$0.35
-2.69%
HEALTHCARE · Cap: $15.32M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 9699652% more annual revenue ($79.67B vs $821,320). LLY leads profitability with a 33.5% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
SCNX
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+61.0%
Fair Value
$1.15
Current Price
$0.35
$0.80 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Reasonable price relative to book value
Revenue surging 449.1% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -0.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : SCNX
The strongest argument for SCNX centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 449.1% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : SCNX
The primary concerns for SCNX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
LLY profiles as a growth stock while SCNX is a hypergrowth play — different risk/reward profiles.
SCNX carries more volatility with a beta of 3.98 — expect wider price swings.
SCNX is growing revenue faster at 449.1% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 33/100), backed by strong 33.5% margins and 47.7% revenue growth. SCNX offers better value entry with a 61.0% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Scienture Holdings, Inc.
HEALTHCARE · PHARMACEUTICAL RETAILERS · USA
Scienture Holdings, Inc. (SCNX) is a pioneering biotechnology firm focused on transforming the treatment landscape for neurological disorders through its advanced drug development pipeline and a seasoned research team. The company is dedicated to addressing significant unmet medical needs, highlighting its potential to enhance patient outcomes while skillfully navigating regulatory complexities. With a strong emphasis on scientific integrity and strategic collaborations, Scienture is well-positioned to leverage growth opportunities in the burgeoning global healthcare market, particularly as the demand for effective neurological therapies continues to rise.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?